Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease
A Phase 4 Study of the Effect on Immune Reconstitution of a Lopinavir/Ritonavir-Based Versus an Efavirenz-based HAART (Highly Active Antiretroviral Therapy) Regimen in Antiretroviral-Naïve Subjects With Advanced HIV Disease
Sponsor: Abbott
Terminated
Study stopped 12/2010 due to poor enrollment. Only 15 of 60 needed enrolled.
Other terminated trials from Abbott
Other Acquired Immune Deficiency Syndrome trials with similar outcome
A PHASE4 clinical study on Acquired Immune Deficiency Syndrome, this trial is terminated or withdrawn. The trial is conducted by Abbott and has accumulated 8 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jun 2023 — Jul 2024 [monthly]
Terminated PHASE4
-
Dec 2021 — Jun 2023 [monthly]
Terminated PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE4
First recorded
Oct 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott
- Gilead Sciences
- Rush University Medical Center
- Ruth M. Rothstein CORE Center
- University of Chicago
- University of Illinois at Chicago
For direct contact, visit the study record on ClinicalTrials.gov .